Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer

Total Page:16

File Type:pdf, Size:1020Kb

Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer 1044 Reviews Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer Authors Sahdeo Prasad, Kannokarn Phromnoi, Vivek R. Yadav, Madan M. Chaturvedi, Bharat B. Aggarwal Affiliation Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA Key words Abstract formation, tumor cell survival, proliferation, inva- l" cancer ! sion, angiogenesis, and metastasis. Whereas vari- l" inflammation Observational studies have suggested that life- ous lifestyle risk factors have been found to acti- l" flavonoids style risk factors such as tobacco, alcohol, high- vate NF-κB and NF-κB-regulated gene products, l" NF‑κB fat diet, radiation, and infections can cause cancer flavonoids derived from fruits and vegetables l" fruits l" vegetables and that a diet consisting of fruits and vegetables have been found to suppress this pathway. The can prevent cancer. Evidence from our laboratory present review describes various flavones, flava- and others suggests that agents either causing or nones, flavonols, isoflavones, anthocyanins, and preventing cancer are linked through the regula- chalcones derived from fruits, vegetables, le- tion of inflammatory pathways. Genes regulated gumes, spices, and nuts that can suppress the by the transcription factor NF-κB have been proinflammatory cell signaling pathways and shown to mediate inflammation, cellular trans- thus can prevent and even treat the cancer. Introduction cancers and the observed changes in the inci- ! dence of cancer in migrating populations. For ex- Despite spending billions of dollars in research, a ample, Ho [4] showed that although the Chinese great deal of understanding of the causes and cell in Shanghai will have a cancer incidence of 2 cases signaling pathways that lead to the disease, can- per 100 000 population, among those who mi- cer continues to be a major killer worldwide. Ac- grate to the United States, the incidence increases cording to a recent statistical analysis, a total of to 23 per 100000 within 5 years. In contrast, 1479350 new cancer cases and 562340 deaths among US-born persons of Chinese descent the from cancer occurred in the United States in cancer incidence is 37 cases per 100 000 popula- received February 23, 2010 2009 [1]. Unlike heart disease, death rates for can- tions, compared with 58 per 100000 among revised June 8, 2010 cer remained approximately the same in the whites. This indicates that lifestyle plays a major accepted June 10, 2010 United States from 1975 through 2002. Indeed, it role in the development of cancer. The important Bibliography is predicted that by 2020 approximately 15 mil- lifestyle factors that affect the incidence and mor- DOI http://dx.doi.org/ lion new cancer cases will be diagnosed world- tality of cancer include tobacco, alcohol, diet, obe- 10.1055/s-0030-1250111 wide and 12 million cancer patients will die [2]. sity, infectious agents, environmental pollutants, Published online July 15, 2010 One of the most important findings to have and radiation. All of these risk factors are linked Planta Med 2010; 76: emerged during the past three decades is that to each other through inflammation. 1044–1063 © Georg Thieme Verlag KG Stuttgart · New York · cancer is a preventable disease. Thus, people need Inflammation is a localized reaction of tissue to ISSN 0032‑0943 to be educated about the risk factors for cancer infection, irritation, or other injury. As defined by and those that prevent the disease. As many as Rudolf Virchow in 1863, the key features of in- Correspondence Bharat B. Aggarwal 90% of all cancers have been shown to be due to flammation are redness, warmth, swelling, pain, M.D. Anderson Cancer Center environmental/acquired factors such as tobacco, and sometimes loss of movement or function. In- The University of Texas diet, radiation, and infectious organisms, etc., flammation is a necessary response to clear viral 1515 Holcombe Blvd. – Box 143 and only the remaining 5 10% of cases are caused infections, repair tissue insults, and suppress tu- Houston, TX 77030 by internal factors such as inherited mutations, mor initiation/progression. However, when in- USA hormones, and immune conditions [3]. flammation persists or control mechanisms are Phone: + 17137941817 Fax: + 171 37456339 A strong link between diet and cancer is indicated dysregulated, disease may develop, including [email protected] by the large variation in incidence rates of specific cancer. Interestingly, inflammation functions at Prasad S et al. Targeting Inflammatory Pathways… Planta Med 2010; 76: 1044–1063 Reviews 1045 all three stages of tumor development: initiation, progression, survival, invasion, and angiogenesis. Those that can suppress car- and metastasis. During the initiation phase, inflammation indu- cinogenesis are discussed in detail below. ces the release of a variety of cytokines and chemokines that pro- mote the activation of inflammatory cells and associated factors. This causes further oxidative damage, DNA mutations, and other Association of Inflammation with Cancer changes in the tissue microenvironment, making it more condu- ! cive to cell transformation, increased survival, and proliferation. There is a strong association between chronic inflammatory con- At the molecular level, inflammation, transformation, survival, ditions and cancer specific to the organ. Epidemiological evi- and proliferation are regulated by nuclear factor κB(NF-κB), a dence points to a connection between inflammation and a pre- family of ubiquitously expressed transcription factors. NF-κBis disposition for the development of cancer, i.e., long-term inflam- activated by various inducers such as tobacco, alcohol, infections, mation leads to the development of dysplasia. Various factors are ionizing radiation, environmental pollutants, chemotherapeutic known to induce chronic inflammatory responses that further agents, and tumor necrosis factor-α (TNF-α). TNF-α is also one of cause cancer. These include bacterial, viral, and parasitic infec- the prime signals that induces apoptosis in many different types tions (e.g., Helicobacter pylori, Epstein-Barr virus, human immu- of cells. Whereas acute activation of NF-κB may be therapeutic, nodeficiency virus, flukes, schistosomes), chemical irritants (i.e., chronic activation may lead to the development of chronic in- tumor promoters, such as phorbol ester 12-O-tetradecanoyl-13- flammation, cancer, and other chronic diseases. NF-κB has been phorbol acetate, also known as phorbol myristate acetate), and associated with increased survival in many tumor cells; thus, its non-digestible particles (e.g., asbestos, silica) [25,26]. Epidemiol- inhibition could be a novel approach to breaking the vicious cycle ogical studies estimate that nearly 15% of the worldwide cancer of tumor cell proliferation. incidence is associated with microbial infection [27]. It is mechanistically proven that inflammation produces reactive oxygen species (ROS) and reactive nitrogen species (RNS). In par- What is NF-κB? ticular, ROS and RNS lead to oxidative damage and nitration of ! DNA bases, which increases the risk of DNA mutations and fur- NF-κB was first identified in 1986 by Sen and Baltimore [5]. In its ther leads to cancer [28]. The most thoroughly studied examples resting stage, this factor resides in the cytoplasm as a hetero- of inflammation and cancer are chronic inflammatory bowel dis- trimer consisting of p50, p65, and IκBα. The inhibitor IκBα masks ease and the increased risk of colorectal cancer, chronic gastritis the NF-κB nuclear localization domain and inhibits its DNA-bind- resulting from H. pylori infection and gastric adenocarcinoma, ing activity. In response to a large variety of stimuli, the IκB inhib- and chronic hepatitis and liver cancer. Chronic hepatitis B infec- itor is rapidly phosphorylated and degraded. This allows NF-κB tion leads to about a 10-fold increase in the risk of liver cancer nuclear translocation, DNA binding to specific recognition se- [29]. quences in promoters, and transcription of the target genes [6, Inflammation results in the recruitment of leukocytes secreting a 7]. The kinase that causes the phosphorylation of IκBα is called variety of proliferative cytokines and angiogenic factors to the IκBα kinase (IKK). IKKβ mediates the classic/canonical NF-κBacti- site of tissue insult. These cytokines are known to be required vation pathway, and IKKα mediates the non-canonical pathway. for proper wound healing, and stimulate epithelial cell prolifera- On activation, NF-κB induces the expression of more than 400 tion; however, if these are uncontrolled they could lead to dyspla- genes that have been shown to suppress apoptosis and induce sias and ultimately cancer. Tumor cells themselves also produce cellular transformation, proliferation, invasion, metastasis, che- various cytokines and chemokines that attract leukocytes, which moresistance, radioresistance, and inflammation [8,9]. The acti- in turn produce cytokines and chemokines that stimulate further vated form of NF-κB has been found to mediate different diseases, tumor cell proliferation. Paradoxically, cytokine deficiency (e.g., including cancer [8,10], atherosclerosis [11], myocardial infarc- GM‑CSF, IL-2 and IFNγ) can also lead to tumor development. Im- tion [12], diabetes [13] allergy [14,15], asthma [16], arthritis mune homeostasis consists of a succession of pro- and anti-in- [17], Crohnʼs disease [18], multiple sclerosis [19],
Recommended publications
  • Isolation, Identification and Characterization of Allelochemicals/Natural Products
    Isolation, Identification and Characterization of Allelochemicals/Natural Products Isolation, Identification and Characterization of Allelochemicals/Natural Products Editors DIEGO A. SAMPIETRO Instituto de Estudios Vegetales “Dr. A. R. Sampietro” Universidad Nacional de Tucumán, Tucumán Argentina CESAR A. N. CATALAN Instituto de Química Orgánica Universidad Nacional de Tucumán, Tucumán Argentina MARTA A. VATTUONE Instituto de Estudios Vegetales “Dr. A. R. Sampietro” Universidad Nacional de Tucumán, Tucumán Argentina Series Editor S. S. NARWAL Haryana Agricultural University Hisar, India Science Publishers Enfield (NH) Jersey Plymouth Science Publishers www.scipub.net 234 May Street Post Office Box 699 Enfield, New Hampshire 03748 United States of America General enquiries : [email protected] Editorial enquiries : [email protected] Sales enquiries : [email protected] Published by Science Publishers, Enfield, NH, USA An imprint of Edenbridge Ltd., British Channel Islands Printed in India © 2009 reserved ISBN: 978-1-57808-577-4 Library of Congress Cataloging-in-Publication Data Isolation, identification and characterization of allelo- chemicals/natural products/editors, Diego A. Sampietro, Cesar A. N. Catalan, Marta A. Vattuone. p. cm. Includes bibliographical references and index. ISBN 978-1-57808-577-4 (hardcover) 1. Allelochemicals. 2. Natural products. I. Sampietro, Diego A. II. Catalan, Cesar A. N. III. Vattuone, Marta A. QK898.A43I86 2009 571.9’2--dc22 2008048397 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying or otherwise, without the prior permission of the publisher, in writing. The exception to this is when a reasonable part of the text is quoted for purpose of book review, abstracting etc.
    [Show full text]
  • IN SILICO ANALYSIS of FUNCTIONAL Snps of ALOX12 GENE and IDENTIFICATION of PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS
    Tulasidharan Suja Saranya et al. Int. Res. J. Pharm. 2014, 5 (6) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Research Article IN SILICO ANALYSIS OF FUNCTIONAL SNPs OF ALOX12 GENE AND IDENTIFICATION OF PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS LIPOXYGENASE INHIBITORS Tulasidharan Suja Saranya, K.S. Silvipriya, Manakadan Asha Asokan* Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Viswa Vidyapeetham University, AIMS Health Sciences Campus, Kochi, Kerala, India *Corresponding Author Email: [email protected] Article Received on: 20/04/14 Revised on: 08/05/14 Approved for publication: 22/06/14 DOI: 10.7897/2230-8407.0506103 ABSTRACT Cancer is a disease affecting any part of the body and in comparison with normal cells there is an elevated level of lipoxygenase enzyme in different cancer cells. Thus generation of lipoxygenase enzyme inhibitors have suggested being valuable. Individual variation was identified by the functional effects of Single Nucleotide Polymorphisms (SNPs). 696 SNPs were identified from the ALOX12 gene, out of which 73 were in the coding non-synonymous region, from which 8 were found to be damaging. In silico analysis was performed to determine naturally occurring flavonoids such as isoflavones having the basic 3- phenylchromen-4-one skeleton for the pharmacological activity, like Genistein, Diadzein, Irilone, Orobol and Pseudobaptigenin. O-methylated isoflavones such as Biochanin, Calycosin, Formononetin, Glycitein, Irigenin, 5-O-Methylgenistein, Pratensein, Prunetin, ψ-Tectorigenin, Retusin and Tectorigenine were also used for the study. Other natural products like Aesculetin, a coumarin derivative; flavones such as ajoene and baicalein were also used for the comparative study of these natural compounds along with acteoside and nordihydroguaiaretic acid (antioxidants) and active inhibitors like Diethylcarbamazine, Zileuton and Azelastine as standard for the computational analysis.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Chronic Venous Insufficiency/CVI
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Chronic Venous Insufficiency/CVI Chemical Activity Count (+)-AROMOLINE 1 (+)-CATECHIN 5 (+)-GALLOCATECHIN 1 (+)-HERNANDEZINE 1 (+)-PRAERUPTORUM-A 1 (+)-SYRINGARESINOL 1 (+)-SYRINGARESINOL-DI-O-BETA-D-GLUCOSIDE 1 (-)-ACETOXYCOLLININ 1 (-)-APOGLAZIOVINE 1 (-)-BISPARTHENOLIDINE 1 (-)-BORNYL-CAFFEATE 1 (-)-BORNYL-FERULATE 1 (-)-BORNYL-P-COUMARATE 1 (-)-CANADINE 1 (-)-EPICATECHIN 4 (-)-EPICATECHIN-3-O-GALLATE 1 (-)-EPIGALLOCATECHIN 1 (-)-EPIGALLOCATECHIN-3-O-GALLATE 2 (-)-EPIGALLOCATECHIN-GALLATE 3 (-)-HYDROXYJASMONIC-ACID 1 (-)-N-(1'-DEOXY-1'-D-FRUCTOPYRANOSYL)-S-ALLYL-L-CYSTEINE-SULFOXIDE 1 (1'S)-1'-ACETOXYCHAVICOL-ACETATE 1 (2R)-(12Z,15Z)-2-HYDROXY-4-OXOHENEICOSA-12,15-DIEN-1-YL-ACETATE 1 (7R,10R)-CAROTA-1,4-DIENALDEHYDE 1 (E)-4-(3',4'-DIMETHOXYPHENYL)-BUT-3-EN-OL 1 1,2,6-TRI-O-GALLOYL-BETA-D-GLUCOSE 1 1,7-BIS(3,4-DIHYDROXYPHENYL)HEPTA-4E,6E-DIEN-3-ONE 1 Chemical Activity Count 1,7-BIS(4-HYDROXY-3-METHOXYPHENYL)-1,6-HEPTADIEN-3,5-DIONE 1 1,8-CINEOLE 1 1-(METHYLSULFINYL)-PROPYL-METHYL-DISULFIDE 1 1-ETHYL-BETA-CARBOLINE 1 1-O-(2,3,4-TRIHYDROXY-3-METHYL)-BUTYL-6-O-FERULOYL-BETA-D-GLUCOPYRANOSIDE 1 10-ACETOXY-8-HYDROXY-9-ISOBUTYLOXY-6-METHOXYTHYMOL 1 10-GINGEROL 1 12-(4'-METHOXYPHENYL)-DAURICINE 1 12-METHOXYDIHYDROCOSTULONIDE 1 13',II8-BIAPIGENIN 1 13-HYDROXYLUPANINE 1 14-ACETOXYCEDROL 1 14-O-ACETYL-ACOVENIDOSE-C 1 16-HYDROXY-4,4,10,13-TETRAMETHYL-17-(4-METHYL-PENTYL)-HEXADECAHYDRO- 1 CYCLOPENTA[A]PHENANTHREN-3-ONE 2,3,7-TRIHYDROXY-5-(3,4-DIHYDROXY-E-STYRYL)-6,7,8,9-TETRAHYDRO-5H-
    [Show full text]
  • Ep 3138585 A1
    (19) TZZ¥_¥_T (11) EP 3 138 585 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.03.2017 Bulletin 2017/10 A61L 27/20 (2006.01) A61L 27/54 (2006.01) A61L 27/52 (2006.01) (21) Application number: 16191450.2 (22) Date of filing: 13.01.2011 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • Gousse, Cecile GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO 74230 Dingy Saint Clair (FR) PL PT RO RS SE SI SK SM TR • Lebreton, Pierre Designated Extension States: 74000 Annecy (FR) BA ME •Prost,Nicloas 69440 Mornant (FR) (30) Priority: 13.01.2010 US 687048 26.02.2010 US 714377 (74) Representative: Hoffmann Eitle 30.11.2010 US 956542 Patent- und Rechtsanwälte PartmbB Arabellastraße 30 (62) Document number(s) of the earlier application(s) in 81925 München (DE) accordance with Art. 76 EPC: 15178823.9 / 2 959 923 Remarks: 11709184.3 / 2 523 701 This application was filed on 29-09-2016 as a divisional application to the application mentioned (71) Applicant: Allergan Industrie, SAS under INID code 62. 74370 Pringy (FR) (54) STABLE HYDROGEL COMPOSITIONS INCLUDING ADDITIVES (57) The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions. EP 3 138 585 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 138 585 A1 Description CROSS REFERENCE 5 [0001] This patent application is a continuation-in-part of U.S.
    [Show full text]
  • Isolation and Identification of Chemical Constituents from Zhideke Granules by Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry
    Hindawi Journal of Analytical Methods in Chemistry Volume 2020, Article ID 8889607, 16 pages https://doi.org/10.1155/2020/8889607 Research Article Isolation and Identification of Chemical Constituents from Zhideke Granules by Ultra-Performance Liquid Chromatography Coupled with Mass Spectrometry Guangqiang Huang ,1 Jie Liang ,1,2,3 Xiaosi Chen,1 Jing Lin,1 Jinyu Wei,1 Dongfang Huang,1 Yushan Zhou,1 Zhengyi Sun,4 and Lichun Zhao 1,3 1College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China 2Guangxi Key Laboratory of Zhuang and Yao Ethnic Medicine, Nanning 530200, China 3Guangxi Zhuang Yao Medicine Center of Engineering and Technology, Nanning 530200, China 4Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530011, China Correspondence should be addressed to Jie Liang; [email protected] and Lichun Zhao; [email protected] Received 25 August 2020; Accepted 8 December 2020; Published 29 December 2020 Academic Editor: Luca Campone Copyright © 2020 Guangqiang Huang et al. ,is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Chemical constituents from Zhideke granules were rapidly isolated and identified by ultra-performance liquid chromatography (UPLC) coupled with hybrid quadrupole-orbitrap mass spectrometry (MS) in positive and negative ion modes using both full scan and two-stage threshold-triggered mass modes. ,e secondary fragment ion information of the target compound was selected and compared with the compound reported in databases and related literatures to further confirm the possible compounds. A total of 47 chemical constituents were identified from the ethyl acetate extract of Zhideke granules, including 21 flavonoids and glycosides, 9 organic acids, 4 volatile components, 3 nitrogen-containing compounds, and 10 other compounds according to the frag- mentation patterns, relevant literature, and MS data.
    [Show full text]
  • Natural Products As Chemopreventive Agents by Potential Inhibition of the Kinase Domain in Erbb Receptors
    Supplementary Materials: Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErBb Receptors Maria Olivero-Acosta, Wilson Maldonado-Rojas and Jesus Olivero-Verbel Table S1. Protein characterization of human HER Receptor structures downloaded from PDB database. Recept PDB resid Resolut Name Chain Ligand Method or Type Code ues ion Epidermal 1,2,3,4-tetrahydrogen X-ray HER 1 2ITW growth factor A 327 2.88 staurosporine diffraction receptor 2-{2-[4-({5-chloro-6-[3-(trifl Receptor uoromethyl)phenoxy]pyri tyrosine-prot X-ray HER 2 3PP0 A, B 338 din-3-yl}amino)-5h-pyrrolo 2.25 ein kinase diffraction [3,2-d]pyrimidin-5-yl]etho erbb-2 xy}ethanol Receptor tyrosine-prot Phosphoaminophosphonic X-ray HER 3 3LMG A, B 344 2.8 ein kinase acid-adenylate ester diffraction erbb-3 Receptor N-{3-chloro-4-[(3-fluoroben tyrosine-prot zyl)oxy]phenyl}-6-ethylthi X-ray HER 4 2R4B A, B 321 2.4 ein kinase eno[3,2-d]pyrimidin-4-ami diffraction erbb-4 ne Table S2. Results of Multiple Alignment of Sequence Identity (%ID) Performed by SYBYL X-2.0 for Four HER Receptors. Human Her PDB CODE 2ITW 2R4B 3LMG 3PP0 2ITW (HER1) 100.0 80.3 65.9 82.7 2R4B (HER4) 80.3 100 71.7 80.9 3LMG (HER3) 65.9 71.7 100 67.4 3PP0 (HER2) 82.7 80.9 67.4 100 Table S3. Multiple alignment of spatial coordinates for HER receptor pairs (by RMSD) using SYBYL X-2.0. Human Her PDB CODE 2ITW 2R4B 3LMG 3PP0 2ITW (HER1) 0 4.378 4.162 5.682 2R4B (HER4) 4.378 0 2.958 3.31 3LMG (HER3) 4.162 2.958 0 3.656 3PP0 (HER2) 5.682 3.31 3.656 0 Figure S1.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0170186 A1 Geers Et Al
    US 2003O1701.86A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0170186 A1 Geers et al. (43) Pub. Date: Sep. 11, 2003 (54) NOVEL FLAVONE GLYCOSIDE (52) U.S. Cl. .................................... 424/59; 514/27; 536/8 DERIVATIVES FOR USE IN COSMETICS, PHARMACEUTICALS AND NUTRITION (57) ABSTRACT (76) Inventors: Bernadette Geers, Duesseldorf (DE); The invention relates to flavone and isoflavone glycoside Ralf Otto, Bad Friedrichshall (DE); derivatives of general formula (I): A-C(=O)0), X Albrecht Weiss, Langenfeld (DE); Dirk O-Z-O-C(=O)-A) (I), wherein X-O-Z represents a Petersohn, Koeln (DE); Klaus Rudolf flavone or isoflavone glycoside Structure, wherein X repre Schroeder, Mettmann (DE); Kordula Sents a flavone or isoflavone parent Substance of formula Schlotmann, Duesseldorf (DE) (IIa) or (IIb), said (iso)flavone parent Substance being mono or multisubstituted and/or mono- or multireduced (hydro Correspondence Address: genated), wherein Z (Sugar) represents a mono-, di- or COGNIS CORPORATION polysaccharide which is acetally bonded to the radical X and 2500 RENAISSANCE BLVD., SUITE 200 is ester-Substituted with A n-times, A-C(=O) represent GULPH MILLS, PA 19406 ing an acyl radical on the flavone or isoflavone parent Substance, wherein A and A, independently of each other, (21) Appl. No.: 10/258,049 represent a polyunsaturated Cs-Cs-alkenyl radical with at least 4 isolated and/or at least 2 conjugated double bonds or (22) PCT Filed: Apr. 11, 2001 an arylaliphatic radical with 1-4 methylene groups between (86) PCT No.: PCT/EPO1/04151 the ester group and the aromatic ring, wherein C(=O)A represents an acyl radical on the Sugar Z, wherein n is a Publication Classification whole number (1,2,3,...) but not 0, wherein m is a whole number including 0 (0,1,2,3,...) and wherein R1,R2 and (51) Int.
    [Show full text]
  • Irigenin Exhibits Anticancer Activity Against Human Colon Cancer Cells
    Zhan et al Tropical Journal of Pharmaceutical Research July 2021; 20 (7): 1357-1363 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v20i7.6 Original Research Article Irigenin exhibits anticancer activity against human colon cancer cells via autophagy, inhibition of cell migration and invasion, and targeting of ERK/MAPK signal pathway Yan Zhan, Shuangxi Kong, Liang Fan, Jun Jiang* Department of Oncology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China *For correspondence: Email: [email protected]; Tel/Fax: 0086-02765696508 Sent for review: 20 October 2020 Revised accepted: 20 June 2021 Abstract Purpose: To study the anticancer effect of naturally-occurring irigenin isoflavonoid on colon cancer, and to determine the mechanism involved. Methods: The effect of irigenin on viability of normal and cancerous colon cells was assessed by MTT assay, while clonogenic assay was used to measure colony generation. Autophagy was examined by transmission electron microscopy (TEM) and western blotting. Transwell chamber assay was used to determine the influence of irigenin isoflavonoid on cell migration and invasion. The expression levels of ERK/MAPK signal pathway-associated proteins were assayed using Western blotting. Results: Irigenin significantly decreased the viability of Caco-2 colon cancer cells, in contrast to normal CCD841 colon cells, and produced concentration-dependent anti-proliferative effects (p < 0.05). The number of cell colonies in control group decreased significantly (p < 0.05) upon exposure to irigenin.
    [Show full text]
  • ( 12 ) United States Patent
    US010722444B2 (12 ) United States Patent ( 10 ) Patent No.: US 10,722,444 B2 Gousse et al. (45 ) Date of Patent : Jul. 28 , 2020 (54 ) STABLE HYDROGEL COMPOSITIONS 4,605,691 A 8/1986 Balazs et al . 4,636,524 A 1/1987 Balazs et al . INCLUDING ADDITIVES 4,642,117 A 2/1987 Nguyen et al. 4,657,553 A 4/1987 Taylor (71 ) Applicant: Allergan Industrie , SAS , Pringy (FR ) 4,713,448 A 12/1987 Balazs et al . 4,716,154 A 12/1987 Malson et al. ( 72 ) 4,772,419 A 9/1988 Malson et al. Inventors: Cécile Gousse , Dingy St. Clair ( FR ) ; 4,803,075 A 2/1989 Wallace et al . Sébastien Pierre, Annecy ( FR ) ; Pierre 4,886,787 A 12/1989 De Belder et al . F. Lebreton , Annecy ( FR ) 4,896,787 A 1/1990 Delamour et al. 5,009,013 A 4/1991 Wiklund ( 73 ) Assignee : Allergan Industrie , SAS , Pringy (FR ) 5,087,446 A 2/1992 Suzuki et al. 5,091,171 A 2/1992 Yu et al. 5,143,724 A 9/1992 Leshchiner ( * ) Notice : Subject to any disclaimer , the term of this 5,246,698 A 9/1993 Leshchiner et al . patent is extended or adjusted under 35 5,314,874 A 5/1994 Miyata et al . U.S.C. 154 (b ) by 0 days. 5,328,955 A 7/1994 Rhee et al . 5,356,883 A 10/1994 Kuo et al . (21 ) Appl . No.: 15 /514,329 5,399,351 A 3/1995 Leshchiner et al . 5,428,024 A 6/1995 Chu et al .
    [Show full text]
  • Pharmacology and Phytochemistry of Isoflavonoids from Iris Species
    Journal of Pharmacology & Clinical Research ISSN: 2473-5574 Review Article J of Pharmacol & Clin Res - Volume 3 Issue 2 July 2017 Copyright © All rights are reserved by Afroze Alam DOI: 10.19080/JPCR.2017.03.555609 Pharmacology and Phytochemistry of Isoflavonoids from Iris Species Disha Choudhary and Afroze Alam*1,2,3 1Institute of Pharmacy, Shri Jagdish Prasad Jhabarmal Tibrewala University, India 2Narayan Institute of Pharmacy, India 3School of Pharmacy, Shoolini University, India Submission: June 16, 2016; Published: July 13, 2017 *Corresponding author: Afroze Alam, Narayan Institute of Pharmacy, Jamuhar, Sasaram (Rohtas)-821305(Bihar)-India, Tel: ; Fax: ; Email: ; Abstract Iris is the largest and most complicated genus of family Iridaceae. Irises are mainly used as the ornamental plants, due to their colorful iris species species of iris have resulted in the isolation of flowers, or in the perfume industry, due to their violet like fragrance, but lot of were also used in many part of the worldsiris as medicinal plants for healing of a wide spectrum of diseases. The phytochemical investigations of various variety of secondary metabolites. Approximately more than two hundred compounds have been reported from the genus which includes flavonoids, isoflavonoids and their glycosides, benzoquinones triterpenoids and stilbenes glycosides. This genus is rich in isoflavonoidsIris which have a wide range of biological activity including anti-inflammatory, antioxidant and cancer chemo preventive properties. Nowadays phytochemical and pharmacological investigations bring new knowledge about chemical compounds in roots, leaves and flowers of the species, about their chemical content and possible pharmacological and medicinal usage. This review brings suchtogether as cancer, results cardiovascular of the iris research disorder, in last and few osteoporosisor decades, putting against together the bacterial the information and viral about infections.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0050398 A1 Bockmuehl Et Al
    US 2008.0050398A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0050398 A1 Bockmuehl et al. (43) Pub. Date: Feb. 28, 2008 (54) COMPOSITION COMPRISING (30) Foreign Application Priority Data BETA-DEFENSIN 2 Mar. 29, 2005 (DE).......................... 10 2005 O14 687.2 (76) Inventors: Dirk Bockmuehl, Wuppertal (DE); Publication Classification He-Marie Hoehne, Duesseldorf (51) Int. Cl. (DE) A6IR 39/02 (2006.01) AOIN 25/00 (2006.01) Correspondence Address: 52) U.S. Cl. ......................................... 424/1901: 424/405 WOODCOCKWASHIBURN LLP (52) s CIRA CENTRE, 12TH FLOOR (57) ABSTRACT 2929 ARCH STREET PHILADELPHIA, PA 19104-2891 (US) The invention relates to compositions comprising at least 9 one peptide with a structure or structural pattern of B-de (21) Appl. No.: 11/864,386 fensin 2 and/or its derivatives, especially human B-defensin 2. The compositions are selected in particular from cosmetic (22) Filed: Sep. 28, 2007 and/or pharmaceutical compositions, cleaning and/or wash ing agents, water-treatment agents and cooling lubricants. Related U.S. Application Data The invention also relates to the use of peptides with a structure or structural pattern of B-defensin 2 and/or its (63) Continuation of application No. PCT/EP2006/ derivatives, especially human f-defensin 2, as an antimi 002760, filed on Mar. 25, 2006. crobial active ingredient in the aforementioned agents. US 2008/0050398 A1 Feb. 28, 2008 COMPOSITION COMPRISING BETA-DEFENSIN 2 0011. There is a need for new antimicrobial agents or compositions containing them, which do not damage the CROSS-REFERENCE TO RELATED skin microflora as comprehensively, to be made available.
    [Show full text]
  • Current Organic Chemistry, 2017, 21, 218-235 REVIEW ARTICLE
    Send Orders for Reprints to [email protected] 218 Current Organic Chemistry, 2017, 21, 218-235 REVIEW ARTICLE ISSN: 1385-2728 eISSN: 1875-5348 Impact Factor: Isoflavones, their Glycosides and Glycoconjugates. Synthesis and Biological Activity 1.949 BENTHAM SCIENCE Wiesaw Szeja1*, Grzegorz Grynkiewicz2 and Aleksandra Rusin3 1Silesian Technical University, Department of Chemistry, Krzywoustego 4, 44-100 Gliwice, Poland; 2Pharmaceutical Research Insti- tute, Rydygiera 8, 01-793 Warszawa, Poland; 3Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Wybrzeze AK 15, 44-100 Gliwice, Poland Abstract: Glycosylation of small biologically active molecules, either of natural or synthetic origin, has a pro- found impact on their solubility, stability, and bioactivity, making glycoconjugates attractive compounds as therapeutic agents or nutraceuticals. A large proportion of secondary metabolites, including flavonoids, occur in plants as glycosides, which adds to the molecular diversity that is much valued in medicinal chemistry studies. The subsequent growing market demand for glycosidic natural products has fueled the development of various chemical and biotechnological methods of glycosides preparation. The review gives an extensive overview of the A R T I C L E H I S T O R Y processes of the synthesis of isoflavones and discusses recently developed major routes towards isoflavone-sugar Received: May 05, 2016 formation processes. Special attention is given to the derivatives of genistein, the main isoflavone recognized as a Revised: July 20, 2016 useful lead in several therapeutic categories, with particular focus on anticancer drug design. The utility of Accepted: September 22, 2016 chemical glycosylations as well as glycoconjugates preparation is discussed in some theoretical as well as practi- DOI: cal aspects.
    [Show full text]